Listen
Reason for request
Amendment to the conditions for inclusion on the list of medicines approved for hospital use for Crohn’s disease in adults (extension of the indication to moderate forms).
-
Clinical Benefit
| Substantial |
The actual benefit of this proprietary medicinal product is substantial. |
Clinical Added Value
| Comments without ASMR value |
Data submitted within the context of the extension of the indication of REMICADE to moderate forms of Crohn's disease after failed treatment with corticosteroids is not sufficient enough to change the IAB level previously given for Crohn's disease. |
English version
Contact Us
Évaluation des médicaments
